|

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

RECRUITINGPhase 4Sponsored by China National Center for Cardiovascular Diseases
Actively Recruiting
PhasePhase 4
SponsorChina National Center for Cardiovascular Diseases
Started2023-11-11
Est. completion2028-03-01
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted

Summary

For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients aged 18 to 75 years;
* clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ;
* undergoing PCI
* baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina.

Exclusion Criteria:

* Severe heart failure (Killip III or IV) or cardiogenic shock;
* Previous hemorrhagic cerebrovascular disease history;
* Uncontrolled or recurrent arrhythmic events;
* poorly controlled hypertension;
* Severe hepatic and renal insufficiency (ALT/AST\> 3 times upper limit of normal, eGFR\<30 ml/kg/1.73m2, or ongoing dialysis) or creatine kinase elevation\>5 times upper limit of normal
* malignant tumor;
* Intolerance to statins or cholesterol absorption inhibitors;
* Intolerance to injections;
* Life expectancy \<1 year;
* poor compliance.

Conditions4

Acute Coronary SyndromeHeart DiseaseLipid Lowering, Vascular InflammationNon ST Segment Elevation Acute Coronary Syndrome

Interventions3

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.